Iran War and Oil Prices: What It Means for Airlines and Aerospace 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Microsoft Azure First to Validate NVIDIA's Vera Rubin NVL72, Signaling a New Era in AI Infrastructure 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Hua Hong Group's 7nm Breakthrough Signals China's Growing Chip Independence 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
JD.com's Joybuy Launches in Europe to Challenge Amazon 
Warner Bros Dominates Oscars Amid $110B Studio Merger With Paramount Skydance 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Intel and Nvidia Join Forces for AI Hardware Development Ahead of GTC 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Stryker Cyberattack Disrupts Operations Amid Iran-Linked Hacking Claims 
Stellantis Shareholder Fraud Lawsuit Dismissed by U.S. Judge 
X Agrees to Overhaul Blue Checkmark System in EU After €120 Million DSA Fine 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Novo Nordisk shares plunged more than 10% in mid-morning trading in Copenhagen on Monday after the pharmaceutical giant announced that its experimental obesity drug, CagriSema, failed to meet a primary endpoint in a closely watched clinical trial. The update intensifies competition in the rapidly expanding weight loss drug market, where Novo Nordisk faces mounting pressure from rival Eli Lilly.
The 84-week open-label head-to-head study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly’s blockbuster obesity treatment, Tirzepatide, in reducing body weight. According to Novo Nordisk, patients treated with CagriSema achieved an average weight loss of 23%, while those receiving Tirzepatide recorded a superior 25.5% reduction. As a result, the trial did not meet its primary objective of proving that CagriSema was not lagging behind Tirzepatide in weight loss efficacy.
The disappointing trial results sent Novo Nordisk stock sharply lower, adding to a challenging year for the Danish drugmaker. In 2025, Novo shares have fallen by 49%, reflecting investor concerns over intensifying competition and shifting dynamics in the obesity treatment sector. The company previously secured a dominant position with its blockbuster drugs Wegovy and Ozempic, both of which fueled significant growth amid surging global demand for weight management medications.
However, competition has grown fiercer, particularly from Eli Lilly, whose Tirzepatide has gained significant traction. Additionally, telehealth providers offering lower-cost compounded alternatives have further pressured pricing and market share.
Despite the setback, Novo Nordisk confirmed that CagriSema was submitted to the U.S. Food and Drug Administration (FDA) for approval in December, with a regulatory decision expected by late 2026. The company recently announced board-level changes, including the appointment of industry veterans and Lars Rebien Sorensen as chairman, signaling a strategic push to strengthen leadership and respond more aggressively to U.S. market challenges.
Investors will now closely monitor regulatory developments and Novo Nordisk’s strategy to defend its position in the booming obesity drug market.
